Should I buy or sell Medicenna Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDNA shares. View MDNA analyst ratings or view top-rated stocks .

What is Medicenna Therapeutics' stock price target for 2024?

2 Wall Street analysts have issued twelve-month price targets for Medicenna Therapeutics' stock. Their MDNA share price targets range from $2.50 to $3.00. On average, they anticipate the company's share price to reach $2.75 in the next twelve months. View analysts price targets for MDNA or view top-rated stocks among Wall Street analysts .

How were Medicenna Therapeutics' earnings last quarter?

Medicenna Therapeutics Corp. (NASDAQ:MDNA) posted its earnings results on Friday, November, 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.03. During the same quarter in the previous year, the business posted ($0.06) earnings per share.

NASDAQ:MDNA

Medicenna Therapeutics (MDNA) Stock Price, News & Analysis

→ Elon Musk’s ChatGPT Could Soon Mint New Millionaires (From InvestorPlace) (Ad)

Free MDNA Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.16
▼
$0.39
52-Week Range: N/A

Volume: 1.27 million shs
Average Volume: 160,047 shs
Market Capitalization: $10.93 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.75

Stock Analysis Analyst Forecasts Earnings Headlines Ownership Social Media

Get Medicenna Therapeutics alerts:

Medicenna Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: ∞ Upside
$2.75 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.17) to ($0.18) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.74 out of 5 stars

Medical Sector

858th out of 928 stocks

Pharmaceutical Preparations Industry

405th out of 434 stocks

3.5

Analyst's Opinion

Consensus Rating
Medicenna Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Medicenna Therapeutics has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for MDNA.

0.0

Dividend Strength

Dividend Yield
Medicenna Therapeutics does not currently pay a dividend.
Dividend Growth
Medicenna Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MDNA.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Medicenna Therapeutics this week, compared to 0 articles on an average week.
MarketBeat Follows
Only 1 people have added Medicenna Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Medicenna Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
33.10% of the stock of Medicenna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 12.38% of the stock of Medicenna Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Medicenna Therapeutics are expected to decrease in the coming year, from ($0.17) to ($0.18) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Medicenna Therapeutics is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Medicenna Therapeutics is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

About Medicenna Therapeutics Stock (NASDAQ:MDNA)

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

MDNA Stock News Headlines

April 11, 2024 | investing.com

Medicenna reports advancement in cancer immunotherapy

April 4, 2024 | finance.yahoo.com

Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

March 1, 2024 | morningstar.com

Medicenna Therapeutics Corp MDNA

February 14, 2024 | finance.yahoo.com

Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update

January 12, 2024 | tmcnet.com

Medicenna Announces Appointment of New Auditor

December 19, 2023 | finance.yahoo.com

Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF

November 20, 2023 | finance.yahoo.com

MDNA.TO: Overall Survival Data from Phase 2b Trial of Bizaxofusp Presented at SNO 2023…

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

November 14, 2023 | finance.yahoo.com

Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights

November 13, 2023 | finance.yahoo.com

MDNA.TO: Additional Confirmed PR in Phase 1/2 ABILITY Trial of MDNA11

November 6, 2023 | finance.yahoo.com

Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

November 3, 2023 | finance.yahoo.com

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

October 30, 2023 | msn.com

Why Is Medicenna Therapeutics (MDNA) Stock Down Today?

October 27, 2023 | finance.yahoo.com

Medicenna Announces Nasdaq Delisting and Cutback of Management Team

October 25, 2023 | finance.yahoo.com

Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors

October 13, 2023 | theglobeandmail.com

Closing Bell: Medicenna Therapeutics Corp up on Thursday (MDNA)

October 10, 2023 | markets.businessinsider.com

Medicenna Therapeutics Names Humphrey Gardner CMO

October 10, 2023 | finance.yahoo.com

Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer

September 28, 2023 | finance.yahoo.com

Medicenna Announces Results of Annual and Special Meeting of Shareholders

September 13, 2023 | nasdaq.com

Medicenna Therapeutics (TSE:MDNA) Price Target Decreased by 12.14% to 3.94

August 22, 2023 | theglobeandmail.com

Closing Bell: Medicenna Therapeutics Corp flat on Monday (MDNA)

August 15, 2023 | msn.com

MDNA: Commences Monotherapy Dose Expansion in Phase 1/2 ABILITY Trial…

August 14, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Medicenna Therapeutics

August 14, 2023 | finance.yahoo.com

Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management

August 8, 2023 | benzinga.com

Medicenna Therapeutics's Earnings: A Preview

August 8, 2023 | benzinga.com

Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee

See More Headlines

Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2021
Today: 4/16/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MDNA
CUSIP: N/A
CIK: 1807983
Web: www.medicenna.com
Phone: (416) 648-5555
Fax: 416-572-7501
Employees: 16
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.75
High Stock Price Target: $3.00
Low Stock Price Target: $2.50
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.09)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,600,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -42.68%
Return on Assets: -35.17%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.57
Quick Ratio: 9.57

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.32 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 69,637,000
Free Float: 46,587,000
Market Cap: $10.93 million
Optionable: Not Optionable
Beta: 1.30

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Fahar Merchant Ph.D. (Age 66)
Founder, Chairman, President & CEO
Comp: $327.41k
Ms. Rosemina Merchant B.Sc. (Age 66)
M.E.Sc, Founder & Chief Development Officer
Comp: $262.62k
Mr. Jeff Caravella M.B.A.
Chief Financial Officer
Mr. Brent Meadows M.B.A.
Chief Business Officer
Dr. Humphrey A. R. Gardner FCAP
M.D., Chief Medical Officer
Dr. Samuel R. Denmeade M.D.
Scientific Advisor

Key Competitors

View All Competitors

MDNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Medicenna Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDNA shares.
View MDNA analyst ratings or view top-rated stocks.
What is Medicenna Therapeutics' stock price target for 2024?: 2 Wall Street analysts have issued twelve-month price targets for Medicenna Therapeutics' stock. Their MDNA share price targets range from $2.50 to $3.00. On average, they anticipate the company's share price to reach $2.75 in the next twelve months.
View analysts price targets for MDNA or view top-rated stocks among Wall Street analysts.
How were Medicenna Therapeutics' earnings last quarter?: Medicenna Therapeutics Corp. (NASDAQ:MDNA) posted its earnings results on Friday, November, 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.03. During the same quarter in the previous year, the business posted ($0.06) earnings per share.

This page (NASDAQ:MDNA) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Medicenna Therapeutics (MDNA) Stock Price, News & Analysis

Medicenna Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Medicenna Therapeutics Stock (NASDAQ:MDNA)

MDNA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

MDNA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™